Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis.
Cutaneous leishmaniasis (LC) is a complex and variable disease in terms of epidemiology, aetiology, pathology and clinical characteristics. The mainstay of treatment is still pentavalent antimony (Sbv) compounds administered systemically, despite their recognized toxicity. The advantages of antimony...
Main Authors: | Nayara C Brito, Tália S Machado de Assis, Ana Rabello, Gláucia Cota |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-12-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | https://doi.org/10.1371/journal.pntd.0007856 |
Similar Items
-
Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.
by: Nayara Castelano Brito, et al.
Published: (2017-01-01) -
Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis
by: Maria Cristina de Oliveira Duque, et al. -
Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
by: Dario Brock Ramalho, et al.
Published: (2018-06-01) -
Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
by: Rosiana Estéfane da Silva, et al.
Published: (2016-08-01) -
Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment
by: Rosiana Estéfane da Silva, et al.